Last reviewed · How we verify
Sativex High Dose
At a glance
| Generic name | Sativex High Dose |
|---|---|
| Also known as | GW-1000-02 |
| Sponsor | GW Pharmaceuticals Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Psilocybin-assisted Treatment for Cannabis Use Disorder (PHASE1)
- Cannabis and Polysubstance Use: Response Inhibition and Stress Exposure (PHASE1)
- Repeated CBD Administration and Cannabis Outcomes (EARLY_PHASE1)
- Pregnenolone as a Treatment for Cannabis Intoxication (PHASE2)
- Tetrahydrocannabinol (THC) and Sleep (EARLY_PHASE1)
- Medical Cannabis for Nausea in Patients Receiving Moderately or Highly Emetogenic Chemotherapy (PHASE2)
- Cannabinoids as a Treatment for Insomnia in Major Depression (PHASE2)
- Effect of Cannabis on Cigarette Use Behavior (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sativex High Dose CI brief — competitive landscape report
- Sativex High Dose updates RSS · CI watch RSS
- GW Pharmaceuticals Ltd portfolio CI